Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene s PCR Reagents Infringe Third Wave s Invader Tech; Jury to Deliberate Damages

Click  here for an updated version of this article.

NEW YORK, Sept. 1 (GenomeWeb News) - A jury has determined that Stratagene's quantitative PCR and RT-PCR reagents infringe two patents held by Third Wave Technologies as part of its Invader technology, Stratagene said today.


The jury, appointed by the United States District Court for the Western District of Wisconsin, found that certain embodiments of Stratagene's FullVelocity technology violate Third Weave's US patents Nos. 6,090,543 and 6,348,314. The jury will now hear arguments with respect to damages.


Third Wave filed the suit  last September. At the time, Stratagene said certain embodiments of its FullVelocity technology are not covered by Third Wave's patents.


In May, Stratagene countersued Third Wave claiming that Third Wave infringes patents that cover its FullVelocity technology. Stratagene's patents are USpatent Nos. 6,350,580; 6,528,254; 6,548,250; 6,589,743; and 6,893,819.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.